Bioxyne : Appendix 4D and Interim Report

For personal use only

21 February 2022

The Company Announcements Office

Australian Securities Exchange Limited

Sydney NSW

Appendix 4D - Half Year Report
1.	Name of Entity	Bioxyne Limited
		ABN 97 084 464 193
	Half year ended	31 December 2021
	Reporting period	1 July 2021 to 31 December 2021
	Previous period	1 July 2020 to 31 December 2020

2. Results for announcement to the market

		31	31	%
		December	December	Change
		2021	2020	Up
				(Down)
2.1	Revenues from continuing	1,358,261	1,210,920	12%
	operations
2.2	Profit/(loss) from operations	4,562	(284,605)	100%+
	after tax attributable to members
2.3	Net profit/(loss) attributable to	4,562	(284,605)	100%+
	members
2.4	Proposed dividends	Nil	Nil
2.5	Record date for determining	N/A	N/A
	dividend

2.6 An explanation of the above figures is contained in the "Review of Operations" included within the attached directors' report.

			%
	31	31	Change
	December	December	Up
	2021	2020	(Down)
3. Net tangible asset per security	0.3 cent	0.3 cent	-

Bioxyne Limited ABN 97 084 464 193, Suite 506, Level 5 50 Clarence Street, Sydney NSW 2000 Telephone [phone] E [e-mail] www.bioxyne.com

only	4.	Details of entities over which control has been gained or lost during the period.
	NIL
5.	There were no payments of dividends during the reporting period.
6.	There is no dividend reinvestment plan in operation.
7.	There are no associates or joint venture entities.
8.	The Company is not a foreign entity.
9.	The accounts are not subject to any audit dispute or qualification.
use	The Company's half year report follows.

For more information, please contact:

Bioxyne Limited

Mr N H Chua | Managing Director [e-mail]

Mr Guy Robertson | Company Secretary [e-mail]

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian health and wellness products company (incorporated in 2000) with a focus on clinically effective health and wellness products particularly in the gut and immune health areas.

Bioxyne is in the consumer dietary supplements and functional foods markets through its proprietary probiotic, Lactobacillus fermentum VRI-003 (PCC®), and through its direct sales business trading as Bioxyne International, the Company has developed a range of functional food and beauty products containing ingredients sourced primarily from New Zealand.

Bioxyne's probiotic business is supported by a manufacturing and distribution agreement with Chr. Hansen (Denmark) a global leader in the manufacturing of natural food additives and supplements products for the

Forfood, health, pharmaceutical and agriculture industries.

Bioxyne has a distribution agreement for PCC® with Nu-Skin Enterprises (USA) a successful worldwide multilevel marketing company.

or more information on Bioxyne, please visit www.bioxyne.com

______________________________________________________________________________________

Bioxyne Limited ABN 97 084 464 193, Suite 506, Level 5 50 Clarence Street, Sydney NSW 2000 Telephone [phone] E [e-mail] www.bioxyne.com

For personal use only

ABN: 97 084 464 193

Suite 506, Level 5

50 Clarence Street

Sydney NSW 2000

BIOXYNE LIMITED

ABN 97 084 464 193

Interim Financial Report

For the Half-Year ended 31 December 2021

For personal use only

Index	Page
Corporate Information	2
Directors' Report	3
Auditor's Independence Declaration	5
Statement of Profit or Loss and Other Comprehensive Income	6
Statement of Financial Position	7
Statement of Changes in Equity	8
Statement of Cash Flows	9
Notes to the Financial Statements	10
Directors' Declaration	15
Independent Auditor's Review Report to the Members	16

1

For personal use only

Bioxyne Limited Half-Year Report

31 December 2021

Corporate Information

This half-year report covers Bioxyne Limited and its controlled entities. The Group's functional and presentation currency is AUD.

A description of the Group's operation is included in the review of operations and activities in the Directors' report on page 3. The Directors' report has not been reviewed by the auditors and does not form part of the financial report.

Directors
Anthony Ho	Non-Executive Chairman
N H Chua	Managing Director
Patrick Douglas Ford	Non-Executive Director
Peter Hughes-Hallett	Non-Executive Director

Chief Financial Officer | Company Secretary

Guy Robertson

Auditors

RSM Australia Partners

Level 13, 60 Castlereagh Street

SYDNEY NSW 2000

Banker

National Australia Bank Limited

255 George Street

Sydney NSW 2000

Share Registry

Automic Pty Limited

Level 35 477 Collins Street,

Melbourne VIC 3000

Registered Office

Level 5 50 Clarence Street

Sydney NSW 2000

Website

www.bioxyne.com

Bioxyne Limited shares (ASX Code: BXN) are listed on the Australian Securities Exchange

2